Psychedelic Science Newsletter
Issue #58October 5, 20267 studies

Psilocybin doesn't change how much neurons fire — it changes how they fire

The psychedelic research pipeline had a busy week — new data on brain circuits, cancer patients, veterans, and a drug nobody had seen before.

The headline finding rewrites a basic assumption about what psilocybin actually does inside the brain.

🧠 Psilocybin Rewires the Brain's Rhythm, Not Its Volume

  • Researchers recorded 46,360 individual neurons across 35 mice simultaneously — one of the largest single-session brain recordings done for any psychedelic study — and found that psilocybin didn't meaningfully change average firing rates across brain regions.
  • What it changed was burst firing: the hippocampus fired in bursts less often, while the thalamus split — one part bursting more, another bursting less. Most of these changes disappeared when researchers blocked a specific serotonin receptor, pointing to that receptor as the key switch.
  • The implication is structural: the psychedelic state may be less about neurons being more or less active overall, and more about the pattern of how they communicate — a distinction that could reshape how researchers think about mechanism and drug design.

Why it matters: If the therapeutic signal lives in burst patterns rather than firing rates, most existing measurement approaches in human trials are probably missing it.

Key Findings

💊 Ketamine Closes the Suicide-Risk Window in Severe Depression

  • A randomized controlled trial found that adding intravenous ketamine to standard antidepressants eliminated the 4–12 week lag period before conventional medications take effect — the stretch when suicide risk peaks.
  • The trial focused on patients with severe but not treatment-resistant depression, a population ketamine research has largely skipped until now.
💡 Ketamine's fastest benefit may be in patients who weren't the target.
Top 50% journal 🔗 Indian journal of psychiatry Journal Article 🗓️ Sep 30

🌿 Single-Dose Ayahuasca Tested in Cancer Patients

  • A feasibility trial administered a single dose of ayahuasca to cancer patients experiencing depression and anxiety — conditions that affect quality of life substantially but have limited treatment options in this population.
  • The study was single-blind and proof-of-concept, so the results signal feasibility rather than confirmed efficacy.
💡 Early signal, small scale — cancer psychiatry is watching this space closely.
🔗 Journal of clinical psychopharmacology Journal Article 🗓️ Sep 29

🔥 Psychedelics Are Anti-Inflammatory — In Mice

  • A systematic review and meta-analysis of 61 studies found that serotonergic psychedelics reliably reduced inflammatory markers in animal models with elevated baseline inflammation, but showed mixed results across the 10 human trials examined.
  • The gap between preclinical and human evidence is wide enough that the authors could not draw conclusions about whether the anti-inflammatory effect translates to people.
💡 Strong in mice, murky in humans — the translation gap remains wide open.

🎖️ Veterans Want Access — and VA Flexibility

  • New data from the 2025 RAND Psychedelics Survey show that veterans report psychedelic use and express policy preferences distinct from nonveterans, including attitudes about whether the VA should expand access to certain substances.
  • PTSD is more prevalent among veterans than the general population, which partly explains why veteran issues dominate media and policy debates around psychedelics.
💡 Veterans are already using psychedelics — policy is the lagging variable.
🔗 Rand health quarterly Journal Article 🗓️ Oct 2

⚠️ A New Designer Psychedelic Turned Up in Seized Capsules

  • Forensic chemists identified ZC-B — a novel hallucinogenic compound structurally related to the phenethylamine family — in capsules seized from drug cases, using mass spectrometry and NMR spectroscopy for full structural confirmation.
  • The substance returned no matches in the NIST spectral library, meaning standard forensic databases would have missed it entirely.
💡 New psychoactive substances are outpacing the detection tools meant to catch them.
Top 30% journal 🔗 Drug testing and analysis Journal Article 🗓️ Oct 1

🤕 TBI Patients Report Cognitive and Emotional Shifts After Psychedelics

  • In a small qualitative study, five adults with traumatic brain injury who had used psychedelics after their injury described reductions in anxiety and trauma-related distress, perceived short-term improvements in memory and clarity, and greater self-acceptance.
  • The study is exploratory and based on self-report — five participants, no control group — but it opens a question that neurorehabilitation research has not formally addressed.
💡 Five people, real experiences — brain injury and psychedelics needs a proper trial.
Top 20% journal 🔗 Frontiers in neurology Journal Article 🗓️ Oct 1

Implications

Psychedelic research is generating findings faster than it's generating the infrastructure to evaluate them — from Oregon's pilot consultation service struggling to assess patient preparedness, to human inflammation data too sparse to interpret. The unresolved tension: burst-firing patterns may be the actual therapeutic signal, but no current human neuroimaging tool can measure them.

Studies in this issue

Primary sources used for this newsletter.

  1. Psilocybin changes brain-wide burst firing patterns through 5-HT2A receptor activity
    main storybioRxiv : the preprint server for biology2026-10-01PMID 42818490
  2. How Common Psychedelic Use Is Among U.S. Veterans and Their Views on Related Policies
    key findingRand health quarterly2026-10-02PMID 42824827
  3. Identification and Structure of ZC-B: A New Synthetic Psychedelic from Seized Illegal Capsules
    key findingDrug testing and analysis2026-10-01PMID 42822460
  4. Psychedelics and their possible role in recovery after brain injury, based on participant stories
    key findingFrontiers in neurology2026-10-01PMID 42818834
  5. Do psychedelics reduce inflammation? A review and analysis of studies on their effects on the immune system
    key findingBrain, behavior, and immunity2026-09-28PMID 42805420
  6. Single Dose of Ayahuasca May Reduce Depression and Anxiety Symptoms Linked to Cancer Diagnosis
    key findingJournal of clinical psychopharmacology2026-09-29PMID 42809662
  7. Adding intravenous ketamine quickly reduces depression and suicidal thoughts in severe major depression
    key findingIndian journal of psychiatry2026-09-30PMID 42812942

Continue reading

All Psychedelic Science issues